Product Description
Vaccinium uliginosum extract; Considering its antioxidative ingredients, the extract of Vaccinium uliginosum is expected to play a significant role in treating various ocular pathologies. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02641470)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Namyi Gu
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02641470 |
DA9301_01 | N/A |
Completed |
Healthy Volunteers |
2014-02-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|